Cramer said any of these companies should see many positive years ahead of them now that the dark days have finally passed.
In the Lightning Round, Cramer was bullish on Akamai Technologies ( AKAM), American Tower ( AMT) and Gilead Sciences ( GILD).
Executive Decision: James Foster
In his second "Executive Decision" segment, Cramer spoke with James Foster, chairman, president and CEO of Charles River Laboratories ( CRL), a supplier to the biotech industry that recently reported a two-cents-a-share earnings miss on lighter-than-expected revenue. Foster explained that with so many big drugs losing patent protection, the drug industry has been more focused than ever on early-phase drug discovery and is putting an emphasis on completing research that's already in the pipeline. Both of those trends are good news for Charles River, which helps drug companies and biotechs by outsourcing much of the drug development work, allowing them to focus on what they do best -- drug discovery. Foster said that for drug companies it's more critical than ever to make go-no go decisions as early in the process as possible. Charles River helps them achieve that goal. When asked about the effects of the government sequester on the company's government sales, Foster said that he is beginning to see some effects of the mandatory budget cuts but expects those effects to be modest. Cramer said that with so much research and development underway, it only makes sense Charles River will be a big beneficiary.
No Huddle Offense
In his "No Huddle Offense" segment, Cramer said those investors betting on a decline in the insurance stocks will be sorely disappointed. He said many of these stocks, including Prudential ( PRU), Hartford ( HIG) and Travelers ( TRV), are springing back to life, which is why he owns Hartford for Action Alerts PLUS. Cramer said that even American International Group ( AIG) is ready to offer investors some juicy returns, which is why now is the time to step up to the plate and buy, buy, buy. To watch replays of Cramer's video segments, visit the Mad Money page on CNBC. -- Written by Scott Rutt in Washington, D.C. To email Scott about this article, click here: Scott Rutt Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC